Lifetime prevention must start before conception - Top-Institutions - MDSpire

Lifetime prevention must start before conception

  • By

  • Lilaf Abdulmajid

  • Sevda Ece Kizilkilic

  • Paul Dendale

  • February 18, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Preventive Cardiology
    • Maternal-Fetal Medicine
    • Epidemiology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Maternal-Fetal Medicine
    • Epidemiology

  • #3

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Preventive Cardiology
    • Maternal-Fetal Medicine
    • Genetics

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Maternal-Fetal Medicine
    • Preventive Medicine

  • #5

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Cardiology
    • Maternal-Fetal Medicine
    • Epidemiology

Original Source(s)

Lifetime prevention must start before conception

  • by Lilaf Abdulmajid, Sevda Ece Kizilkilic, Paul Dendale

  • February 18, 2026

Related Content

Association between blood pressure levels and risk of stroke in patients with atrial fibrillation: results from a prospective registry in Xinjiang, China

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.